99% Purity – Third-Party Tested
Free U.S. Shipping on Orders $100+
Proudly Made in the USA
Fast & Reliable Shipping
Secure Checkout GuaranteedDescription
Orforglipron research compound
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist designed to be orally available, which sets it apart from peptide GLP-1 agonists.
Product details
| Compound | Orforglipron (LY3502970) |
|---|---|
| Class | Oral non-peptide GLP-1 receptor agonist |
| Form | Sublingual Tablets |
| Strength | 6mg per tab/90ct/540mg; 12mg per tab/90ct/1080mg |
| Labelling | Compound name and strength on every container |
Select your format and strength from the options above.
What research has examined
- GLP-1 receptor signalling: biased agonism by a small molecule.
- Oral bioavailability: non-peptide incretin research.
- Clinical research: phase 3 trial programme.
Research interest does not establish a proven effect in humans.
Regulatory status
Orforglipron is investigational in most markets. Supplied as a research chemical only.
Storage and handling
Keep the container tightly closed, at room temperature or cooler, away from moisture and light.
Related research products
Evodiamine · Enclomiphene Citrate · Ibutamoren (MK-677) · All tablets
References
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.